Trial Profile
A phase I study of S-CKD602 [belotecan] in patients with advanced small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Nov 2009
Price :
$35
*
At a glance
- Drugs Belotecan (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 21 Nov 2009 Actual initiation date (16 Sep 2005) added as reported by M.D. Anderson Cancer Center.
- 23 Dec 2005 New trial record.